Bingchuan Xie1, Ping Gu2, Wenting Wang1, Ci Dong1, Lina Zhang1, Jun Zhang3, Huimiao Liu1, Fucheng Qiu1, Rui Han1, Zhenqing Zhang1, Baoyong Yan4. 1. Department of Gerontology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Department of Neurology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China. 2. Department of Gerontology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Department of Neurology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Brain Aging and Cognitive, Neuroscience Laboratory of Hebei ProvinceShijiazhuang 050031, China. 3. The Lab of Cell Therapy, The First Hospital of Hebei Medical University Shijiazhuang 050031, China. 4. Brain Aging and Cognitive, Neuroscience Laboratory of Hebei Province Shijiazhuang 050031, China.
Abstract
OBJECTIVE: Human umbilical cord mesenchymal stem cells (hUC-MSCs) hold substantial promise for the treatment of ischemic neurological disease, but few clinical data are currently available about its therapeutic effects in hypoxic ischemic encephalopathy (HIE). This study is to evaluate the effects of hUC-MSCs transplantation on patients with HIE. Methods A total 22 patients with HIEwere randomly divided into hUC-MSCs transplantation group (n = 12) and control group (n = 10). After isolation, hUC-MSCs were cultured for 3 to 5 passages in vitro and then intravenously administered to HIE patients in the transplantation group, while the control group received routine treatment only. The outcomes of HIE patients were evaluated at designated time points by clinical assessment scales, including NIHSS, Barthel Index, MMSE, HAMA24, HAMD14 and UPDRS. RESULTS: hUC-MSCs were identified by morphological analysis and flow cytometry assays before clinic transplantation. No significant differences of demographic characteristics were observed between the two groups of subjects. Compared to the control group, hUC-MSCs transplantation markedly improved the outcomes of HIE patients leading to better recovery of neurological function, cognition ability, emotional reaction and extrapyramidal function. No significant adverse effects were found in subjects with hUC-MSCs transplantation during a 180-day follow-up period. CONCLUSION: These data suggest that hUC-MSCs therapy markedly improves the outcomes of patients with HIE, which is potential for the routine treatment of ischemic neurological disease.
OBJECTIVE:Human umbilical cord mesenchymal stem cells (hUC-MSCs) hold substantial promise for the treatment of ischemic neurological disease, but few clinical data are currently available about its therapeutic effects in hypoxic ischemicencephalopathy (HIE). This study is to evaluate the effects of hUC-MSCs transplantation on patients with HIE. Methods A total 22 patients with HIEwere randomly divided into hUC-MSCs transplantation group (n = 12) and control group (n = 10). After isolation, hUC-MSCs were cultured for 3 to 5 passages in vitro and then intravenously administered to HIEpatients in the transplantation group, while the control group received routine treatment only. The outcomes of HIEpatients were evaluated at designated time points by clinical assessment scales, including NIHSS, Barthel Index, MMSE, HAMA24, HAMD14 and UPDRS. RESULTS: hUC-MSCs were identified by morphological analysis and flow cytometry assays before clinic transplantation. No significant differences of demographic characteristics were observed between the two groups of subjects. Compared to the control group, hUC-MSCs transplantation markedly improved the outcomes of HIEpatients leading to better recovery of neurological function, cognition ability, emotional reaction and extrapyramidal function. No significant adverse effects were found in subjects with hUC-MSCs transplantation during a 180-day follow-up period. CONCLUSION: These data suggest that hUC-MSCs therapy markedly improves the outcomes of patients with HIE, which is potential for the routine treatment of ischemic neurological disease.
Entities:
Keywords:
Human umbilical cord mesenchymal stem cells; hypoxic-ischemic encephalopathy; transplantation
Authors: Nate Watson; Ryan Divers; Roshan Kedar; Ankur Mehindru; Anuj Mehindru; Mia C Borlongan; Cesar V Borlongan Journal: Cytotherapy Date: 2014-10-18 Impact factor: 5.414
Authors: Mary Thompson; Shirley H J Mei; Dianna Wolfe; Josée Champagne; Dean Fergusson; Duncan J Stewart; Katrina J Sullivan; Emily Doxtator; Manoj Lalu; Shane W English; John Granton; Brian Hutton; John Marshall; Alies Maybee; Keith R Walley; Claudia Dos Santos; Brent Winston; Lauralyn McIntyre Journal: EClinicalMedicine Date: 2020-01-17